Search Within

John Frank Gerecitano

Formats
  1. Meeting Abstract (100)
  2. Journal Article (51)
  3. Book Section (1)
  4. Book Whole (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Center for Hematologic Malignancies (82)
  4. Lymphoma (75)
  5. Survivorship Research (56)
  6. Executive Committee, Center for Hematologic Malignancies (45)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Paul Hamlin (60)
  3. Craig Moskowitz (57)
  4. David Straus (56)
  5. Ariela Noy (50)
  6. Matthew Matasar (48)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (8)

More Years

Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (34)
  3. Haematologica (11)
  4. Clinical Cancer Research (9)
  5. Hematological Oncology (8)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. American Society of Clinical Oncology (34)
  3. American Association for Cancer Research (11)
  4. Ferrata Storti Foundation (11)
  5. Wiley Blackwell (10)
  6. Oxford University Press (7)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Seymour, J. F.; Davids, M. S.; Pagel, J. M.; Kahl, B. S.; Wierda, W. G.; Miller, T. P.; Gerecitano, J. F.; Kipps, T. J.; Anderson, M. A.; Huang, D. C. S.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Infectious disease associations in advanced stage, indolent lymphoma (follicular, FL, and nonfollicular, nFL): A prospective trial of antibiotic therapy
    Meeting Abstract

    Portlock, C. S.; Hamlin, P. A.; Gerecitano, J. F.; Noy, A.; Palomba, M. L.; Walkley, J.; Corcoran, S.; Papanicolaou, G. A.; Markowitz, A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Using (124)I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Gajria, D.; Taldone, T.; Alpaugh, M.; DaGama, E. G.; Uddin, M.; Chiosis, G.; Lewis, J. S.; Larson, S. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Davids, M. S.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Pagel, J. M.; Wierda, W. G.; Anderson, M. A.; Darden, D. E.; Nolan, C. E.; Gressick, L. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • ABT-888 plus bendamustine is safe and has shown preliminary efficacy in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Schwartz, G. K.; Carvajal, R.; Fury, M.; Konner, J.; Hyman, D. M.; Gounder, M.; Gajria, D.; Teitcher, J.; Zhang, Z.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)
    Meeting Abstract

    Seymour, J. F.; Davids, M. S.; Pagel, J. M.; Kahl, B. S.; Wierda, W. G.; Miller, T. P.; Gerecitano, J. F.; Kipps, T. J.; Anderson, M. A.; Huang, D. C. S.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with elapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in all mantle cell lymphoma (MCL) patients
    Meeting Abstract

    Davids, M. S.; Seymour, J. F.; Gerecitano, J. F.; Kahl, B. S.; Pagel, J. M.; Wierda, W. G.; Anderson, M. A.; Rudersdorf, N. K.; Gressick, L. A.; Montalvo, N. P.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • A phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies
    Journal Article

    Gerecitano, J. F.; Stephenson, J. J.; Lewis, N. L.; Osmukhina, A.; Li, J.; Wu, K.; You, Z.; Huszar, D.; Skolnik, J. M.; Schwartz, G. K.
    Investigational New Drugs (2013)

    Fulltext@MSK | Save
  • Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Hamlin, P. A. Jr; Perales, M. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save